Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entry “RNA, U4 small nuclear 86, pseudogene” (RNU4-86P) refers to a pseudogene of a small nuclear RNA (snRNA) gene that would otherwise encode the U4 snRNA, a component of the spliceosome. Pseudogenes are genetic elements that resemble genes but typically do not produce a functional product—here, a functional U4 snRNA—and thus lack direct biological activity. There is no evidence in the scientific literature or major functional databases that RNU4-86P encodes a molecule with known biological activity, cellular function, involvement in disease, or therapeutic relevance. The functional gene encoding human U4 snRNA is RNU4-2 (sometimes also called U4), which is essential for the splicing of pre-mRNA and whose disruption is linked to severe neurodevelopmental disorders; however, RNU4-86P is a nonfunctional remnant and not implicated in these roles[1][2][3][4]. Key clarifications: - RNU4-86P is not a protein, enzyme, receptor, transporter, or therapeutic target of any class. - It is classified as a non-coding RNA pseudogene (sometimes annotated under “Other” for molecular classification). - There are no known disease roles, drug interactions, mechanisms of action, or biomarker applications for RNU4-86P. - The canonical name, abbreviation, and classification here are derived from standard gene nomenclature conventions and the definitions of pseudogenes. If you are interested in the functional small nuclear RNA U4, you should refer to "RNA, U4 small nuclear 2" (RNU4-2 or U4 snRNA)[1][2][3][4]. If you need detailed information about the functional U4 snRNA, please clarify, as the provided entry specifically corresponds to a pseudogene and not a functional molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 86, pseudogene (RNU4-86P).